for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Oramed Pharmaceuticals, Inc.

ORMP.OQ

Latest Trade

3.10USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

2.79

 - 

4.98

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
3.10
Open
--
Volume
--
3M AVG Volume
0.98
Today's High
--
Today's Low
--
52 Week High
4.98
52 Week Low
2.79
Shares Out (MIL)
17.38
Market Cap (MIL)
53.89
Forward P/E
-3.25
Dividend (Yield %)
--

Latest Developments

More

Oramed Provides Clinical Update With Meaningful Data Expected By Year-End

Oramed Pharmaceuticals Appointed Avi Gabay As CFO Effective June 1

Oramed Pharmaceuticals Says CFO Hilla Eisenberg Resigned

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Oramed Pharmaceuticals, Inc.

Oramed Pharmaceuticals Inc. (Oramed) is engaged in the field of oral delivery solutions for drugs and vaccines presently delivered via injection. Oramed’s flagship product, an orally ingestible insulin capsule in phase II clinical trials, is focused on the treatment of diabetes. The Company is developing orally ingestible protein oral delivery (POD) technology for the delivery of drugs presently administered by way of injection. Oramed’s delivery platform protects protein sand enhances their absorption, allowing them to reach the blood stream through the portal vein. The Company’s products include ORMD-0801, Oral insulin capsule; ORMD 0901, Oral Exenatide capsule; and combination therapy of ORMD 0801 + ORMD 0901. ORMD-0801 is under phase II A clinical trials. ORMD-0901 is under preclinical/Investigational New Drug (IND) stage under phase I B.

Industry

Biotechnology & Drugs

Contact Info

1185 Avenue of the Americas Ste 228

+1.646.8441164

http://oramed.com

Executive Leadership

Kevin L. Rakin

Chairman of the Board, Independent Director

Nadav Kidron

President, Chief Executive Officer, Director

Avi Gabay

Chief Financial Officer, Treasurer, Secretary

Miriam Kidron

Chief Scientific Officer, Director

Ronald Edward Law

Chief Strategy Officer

Key Stats

2.00 mean rating - 3 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-0.870

2017

-0.790

2018

-0.860

2019(E)

-0.913
Price To Earnings (TTM)
--
Price To Sales (TTM)
20.42
Price To Book (MRQ)
2.50
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-48.99
Return on Equity (TTM)
-41.62

Latest News

BRIEF-Oramed Initiates Its 90-Day Pivotal Dose-Ranging Clinical Study For Oral Insulin

* ORAMED INITIATES ITS 90-DAY PIVOTAL DOSE-RANGING CLINICAL STUDY FOR ORAL INSULIN Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

BRIEF-Oramed Pharmaceuticals' Unit Enters Clinical Research Organization Services Agreement With Integrium

* SAYS ON FEB 14, A UNIT ENTERED CLINICAL RESEARCH ORGANIZATION SERVICES AGREEMENT WITH INTEGRIUM EFFECTIVE AS OF NOV 1, 2017

BRIEF-Oramed receives approval for clinical study to treat NASH

* Oramed receives regulatory approval to conduct clinical study for treatment of NASH with its oral insulin capsule

BRIEF-Oramed pharmaceuticals ‍concludes its meeting with U.S. FDA regarding its oral insulin formulation​

* Concluded its meeting with U.S. FDA regarding ORMD-0801, company's novel oral insulin formulation

BRIEF-Oramed Pharmaceuticals Inc's CFO Yifat Zommer resigned from her positions with co per personal reasons

* Oramed Pharmaceuticals Inc - on July 18, yifat zommer, cfo of co resigned from her positions with co per personal reasons, effective August 1, 2017

BRIEF-Oramed announces dual-listing on Tel Aviv stock exchange

* Oramed Pharmaceuticals Inc - Based on current market capitalization of company, it is expected that Oramed will be included in TA SME-60 index

BRIEF-Oramed granted Japanese patent for combination insulin and glp-1 analog capsule

* Oramed granted Japanese patent for combination insulin and glp-1 analog capsule

BRIEF-Oramed receives Israel regulatory approval

* Oramed receives Israel regulatory approval to conduct human study for new oral leptin capsule

BRIEF-Oramed Pharmaceuticals Inc files for mixed shelf of up to $100 mln

* Oramed pharmaceuticals inc - files for a mixed shelf of up to $100 million - sec filing Source text (http://bit.ly/2j8k1FJ) Further company coverage:

BRIEF-Oramed's ORMD-0901 safe and well tolerated in phase IB study

* Oramed's ORMD-0901 (oral GLP-1 analog) found safe and well tolerated in phase IB study

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up